Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Total Current Liabilities (2016 - 2026)

Corvus Pharmaceuticals' Total Current Liabilities history spans 12 years, with the latest figure at $12.1 million for Q1 2026.

  • Quarterly Total Current Liabilities rose 30.51% to $12.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $12.1 million through Mar 2026, up 30.51% year-over-year, with the annual reading at $9.4 million for FY2025, 73.5% down from the prior year.
  • Total Current Liabilities came in at $12.1 million for Q1 2026, up from $9.4 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $46.4 million in Q3 2024 to a low of $6.7 million in Q1 2024.
  • The 5-year median for Total Current Liabilities is $9.3 million (2025), against an average of $13.2 million.
  • Year-over-year, Total Current Liabilities skyrocketed 535.79% in 2024 and then crashed 82.6% in 2025.
  • Corvus Pharmaceuticals' Total Current Liabilities stood at $10.8 million in 2022, then tumbled by 36.11% to $6.9 million in 2023, then surged by 415.39% to $35.4 million in 2024, then tumbled by 73.5% to $9.4 million in 2025, then increased by 29.1% to $12.1 million in 2026.
  • Per Business Quant, the three most recent readings for CRVS's Total Current Liabilities are $12.1 million (Q1 2026), $9.4 million (Q4 2025), and $8.1 million (Q3 2025).